Latham & Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLs

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, has announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).

Under the collaboration, the companies will be innovating on their respective platforms — RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs — and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL.

Latham & Watkins LLP advised RxSight in the transaction with a life sciences licensing team led by New York partner Aaron Gardner and San Diego counsel Robert Yeh, with associate Patrick Chew.